Authors: Tsague Marthe Valentine, Mbaga Donatien Serge, Essindi Justin, Njiki Bikoï Jacky, Mane Felix Toussaint, Ze Minkande Jacqueline.
Background: Human immunodeficiency virus (HIV) infection associated with Highly Active Antiretroviral Treatment (HAART) is considered a cause of many hepatobiliary disorders, including elevated liver enzymes, hepatomegaly, and fatty liver.
Aim: To highlight Liver Elevated Enzymes (LEE) in people living with HIV (PLHIV) under HAART treatment.
Methods: This study was cross-sectional and done between June 2022 to August 2022. Participants were PLHIV, adults over 21 years old, followed at the Protestant Hospital of Garoua Boulaï. Venous blood was collected from each participant Alanine aminotransferase (ALT), and aspartate aminotransferase (AST), were measured with a spectrophotometer. SPSS version 23.0. Was used to express proportions and adjusted odds ratios to identify risk factors.
Results: Overall, 131 participants were included in this analysis, all were HIV type 1, and 30% of participants have LEE. Of the 131 patients investigated, we found 69.6% of LEE with HBs Ag and 27.5% of this group found with Antibody HCV. A logistic regression analysis did not show any significant (p<0.05) association between LEE with socio-demographic and clinical variables.
Conclusion: This study shows that the occurrence of LEE is independently influenced by multiple risk factors.
View/Download pdf